ViewRay (NASDAQ:VRAY), a provider of advanced medical equipment & technology, said the company has received China Food and Drug Administration (CFDA) approval for its MRIdian System, the world’s first and only clinical MRI-guided radiation therapy system. The MRIdian system is a unique medical instrument that integrates full-time MR imaging, cobalt radiation delivery, and intelligent software automation to treat cancers throughout the body. Using the MRIdian system, clinicians can see soft tissue, and visualize and adjust the dose — all in real time, on live anatomy. With MRIdian this is done without exposing the patient to the additional ionizing radiation that is common with other imaging modalities. ViewRay is represented in China by Cowealth Medical Holding Co.
The stock decreased 1.10% or $0.04 during the last trading session, hitting $3.58. About 16,187 shares traded hands. Viewray Inc (NASDAQ:VRAY) has declined 26.12% since February 8, 2016 and is downtrending. It has underperformed by 42.61% the S&P500.
ViewRay, Inc. designs, manufactures and markets MRIdian, the magnetic resonance imaging -guided radiation therapy system to image and treat cancer patients simultaneously. The company has a market cap of $139.00 million. The Firm offers radiation therapy technology combined with magnetic resonance imaging. It has a 0.16 P/E ratio. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.